REAL-LIFE STUDY OF BIO-CLINICAL FOLLOW-UP AFTER BNT162b2 mRNA COVID-19 (BNTCV) VACCINATION IN 235 PATIENTS (PTS) INCLUDING 225 WITH HEMATOLOGICAL MALIGNANCIES (HM).

Outros usuários também visualizaram estes artigos

FROM ALLOGENIC TRANSPLANTATION TO PRECISION IMMUNE THERAPY Jean-François Rossi;

Hematol Transfus Cell Ther. 2022;44 Supl 1:S8

INFLAMMATION AND CANCER Jean-François Rossi;

Hematol Transfus Cell Ther. 2021;43 Supl 3:S9